Events & News

Closing the CMC Gap: How Next-Gen Manufacturing Unlocks the True Promise of MSCs

Aug 12,2025

Closing the CMC Gap: How Next-Gen Manufacturing Unlocks the True Promise of MSCs

Following the landmark FDA approval of Mesoblast’s cell therapy, CytoNiche’s 3D platform resolves scalability and cost barriers have long hindered the industry.

>

CytoNiche Biotech Launches 3D FloTrix™ Experience Hub in Singapore, Advancing Affordable Stem Cell Therapy Worldwide

Jul 23,2025

CytoNiche Biotech Launches 3D FloTrix™ Experience Hub in Singapore, Advancing Affordable Stem Cell Therapy Worldwide

Singapore | July 21, 2025 — CytoNiche Biotech celebrated the grand opening of its 3D FloTrix™ Experience Hub in Singapore, marking a pivotal step in globalizing its breakthrough 3D cell manufacturing platform—the technology behind China’s first approved stem cell drug, priced at just 1/70th the cost of comparable therapies (e.g., $194,000/dose in the U.S. vs. ~$2,700/dose in China).

>

< 123 >

We are always looking forward to hear from you.

Security verification
Submit Your Request